Cited by 665Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchBreast Cancer Treatment Studies

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

Open access

Shipley, William U., Seiferheld, Wendy, Lukka, Himanshu R., Major, Pierre P., Heney, Niall M., Grignon, David J., Sartor, Oliver, Patel, Maltibehn P., Bahary, Jean-Paul, Zietman, Anthony L., Pisansky, Thomas M., Zeitzer, Kenneth L., Lawton, Colleen A.F., Feng, Felix Y., Lovett, Richard D., Balogh, Alexander G., Souhami, Luis, Rosenthal, Seth A., Kerlin, Kevin J., Dignam, James J., Pugh, Stephanie L., Sandler, Howard M.·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1607529PMC PMC5444881

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown. METHODS: In a double-blind, placebo-controlled trial conducted from 1998 through 2003, we assigned 760 eligible patients who had undergone prostatectomy with a lymphadenectomy and had disease, as assessed on pathological testing, with a tumor stage of T2 (confined to the prostate but with a positive surgical margin) or T3 (with histologic extension beyond the prostatic capsule), no nodal involvement, and a detectable PSA level of 0.2 to 4.0 ng per milliliter to undergo radiation therapy and receive either antiandrogen therapy (24 months of bicalutamide at a dose of 150 mg daily) or daily placebo tablets during and after radiation therapy. The primary end point was the rate of overall survival. RESULTS: The median follow-up among the surviving patients was 13 years. The actuarial rate of overall survival at 12 years was 76.3% in the bicalutamide group, as compared with 71.3% in the placebo group (hazard ratio for death, 0.77; 95% confidence interval, 0.59 to 0.99; P=0.04). The 12-year incidence of death from prostate cancer, as assessed by means of central review, was 5.8% in the bicalutamide group, as compared with 13.4% in the placebo group (P<0.001). The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the placebo group (P=0.005). The incidence of late adverse events associated with radiation therapy was similar in the two groups. Gynecomastia was recorded in 69.7% of the patients in the bicalutamide group, as compared with 10.9% of those in the placebo group (P<0.001). CONCLUSIONS: The addition of 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long-term overall survival and lower incidences of metastatic prostate cancer and death from prostate cancer than radiation therapy plus placebo. (Funded by the National Cancer Institute and AstraZeneca; RTOG 9601 ClinicalTrials.gov number, NCT00002874 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1607529

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,811
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P. E., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,767
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
Bolla, M., González, D., Warde, P. R., Dubois, J. B., Mirimanoff, R., Storme, G. A., Bernier, J., Kuten, A., Sternberg, C. N., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,547
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, T. M., Slawin, K. M., Klein, E. A., Anscher, M. S., Michalski, J. M., Sandler, H. M., Lin, D. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9607 · Cited by 889
Self-citation
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 3

American Joint Commission on Cancer. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
10.2307/2281868 · DOI · Paper page
Mantel N, 1966, Cancer Chemother Rep, 50, 163

Sorted by citations

The Diagnosis and Treatment of Prostate Cancer
Litwin, M. S., & Tan, H. (2017) · JAMA · doi:10.1001/jama.2017.7248 · Cited by 1,495
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R. G., Carver, B. S., Castellano, D., Chung, B. H., Clarke, N. W., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 648
“But the addition, timing, and duration of ADT, specifically for ART but also for SRT, are less well examined [26].”
BackgroundSelf-citation
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Xie, W., Regan, M. M., Buyse, M. E., Halabi, S., Kantoff, P. W., Sartor, O. A., Soule, H. R., Clarke, N. W., Collette, L., Dignam, J. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9987 · Cited by 437
Self-citation
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Parker, C. C., Clarke, N. W., Cook, A. D., Kynaston, H., Petersen, P. M., Catton, C., Cross, W. R., Logue, J. P., Parulekar, W. R., Payne, H. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31553-1 · Cited by 414
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A. S., Bossi, A., Briganti, A., Bristow, R. G., Chi, K. N., Clarke, N. W., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.01.012 · Cited by 396
“Of note, the study included patients with PSA persistence as well as PSA recurrence [31].”
BackgroundSelf-citation
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
Kneebone, A. B., Fraser‐Browne, C., Duchesne, G. M., Fisher, R., Frydenberg, M., Herschtal, A., Williams, S., Brown, C. S. B., Delprado, W., Haworth, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30456-3 · Cited by 373
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Tilki, D., van den Bergh, R. C. N., Briers, E., den Broeck, T. V., Brunckhorst, O., Darraugh, J., Eberli, D., Meerleer, G. D., Santis, M. D., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 407
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
Sargos, P., Chabaud, S., Latorzeff, I., Magné, N., Benyoucef, A., Supiot, S., Pasquier, D., Abdiche, M. S., Gilliot, O., Graff-Cailleaud, P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30454-x · Cited by 331
A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)
Valle, L., Lehrer, E. J., Markovic, D., Elashoff, D. A., Levin-Epstein, R. G., Karnes, R. J., Reiter, R. E., Rettig, M. B., Calais, J., Nickols, N. G., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.11.010 · Cited by 320
“Emerging data in the postprostatectomy setting suggest a benefit of combining ADT with salvage radiotherapy [29,30], although patient selection remains the key [31].”
Background
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
Zhao, S. G., Chang, S. L., Erho, N., Yu, M., Lehrer, J. M., Alshalalfa, M., Speers, C. W., Cooperberg, M. R., Kim, W. B., Ryan, C. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0751 · Cited by 306
Self-citation
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
Pollack, A. S., Karrison, T. G., Balogh, A. G., Gomella, L. G., Low, D. A., Bruner, D. W., Wefel, J. S., Martin, A., Michalski, J. M., Angyalfi, S. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01790-6 · Cited by 270
Self-citation
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial
Carrié, C., Magné, N., Burban-Provost, P., Sargos, P., Latorzeff, I., Lagrange, J., Supiot, S., Belkacémi, Y., Peiffert, D., Allouache, N., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30486-3 · Cited by 261
Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review
Artibani, W., Porcaro, A. B., MARCO, V. D., Cerruto, M. A., & Siracusano, S. (2017) · Urologia Internationalis · doi:10.1159/000481438 · Cited by 215
Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer
Spratt, D. E., Zhang, J., Santiago‐Jiménez, M., Dess, R. T., Davis, J. W., Den, R. B., Dicker, A. P., Kane, C. J., Pollack, A. S., Stoyanova, R. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2940 · Cited by 211
Self-citation
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial
Jani, A. B., Schreibmann, E., Goyal, S., HALKAR, R. K., Hershatter, B. W., Rossi, P. J., Shelton, J. W., Patel, P. R., Xu, K. M., Goodman, M. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00581-x · Cited by 189
Nuclear receptors: recent drug discovery for cancer therapies
Zhao, L., Zhou, S., & Gustafsson, J.-Α. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00222 · Cited by 163
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer
Feng, F. Y.-C., Huang, H.-C. R., Spratt, D. E., Zhao, S. G., Sandler, H. M., Simko, J., Davicioni, E., Nguyen, P. L., Pollack, A. S., Efstathiou, J. A., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7671 · Cited by 155
Self-citation
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification
Shore, N. D., Moul, J. W., Pienta, K. J., Czernin, J. G., King, M. T., & Freedland, S. J. (2023) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00712-z · Cited by 165
“As the evidence published thus far only demonstrates a modest clinical bene ﬁ t in OS for early ADT and that side effects associated with chronic ADT therapy are an important consideration, only high-risk patients should consider early ADT according to both NCCN and European guidelines (de ﬁ ned by…”
Background
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy
Bleser, E. D., Jereczek‐Fossa, B. A., Pasquier, D., Zilli, T., van As, N. J., Siva, S., Fodor, A., Dirix, P. R., Iturriaga, A. G., Trippa, F., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.07.009 · Cited by 142
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Gillessen, S., Turco, F., Davis, I. D., Efstathiou, J. A., Fizazi, K. S., James, N. D., Shore, N. D., Small, E. J., Smith, M. R., Sweeney, C. J., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.09.017 · Cited by 150
Self-citation
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Heymach, J. V., Krilov, L., Alberg, A. J., Baxter, N. N., Chang, S. M., Corcoran, R. B., Dale, W., DeMichele, A. M., Diefenbach, C., Dreicer, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0446 · Cited by 142
“A recent large clinical trial found that adding androgendeprivation therapy to radiation therapy helps men, who experience a local recurrence after surgery, live longer (this study was funded, in part, by a grant from the NCI).(72) The study enrolled men with prostate-specific antigen levels between 0.”
BackgroundInfluential
Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019
Pisansky, T. M., Thompson, I. M., Valicenti, R. K., D'Amico, A. V., & Selvarajah, S. (2019) · The Journal of Urology · doi:10.1097/ju.0000000000000295 · Cited by 132
“In addition, evidence from the RTOG 9601 and the GETUG-AFU 16 trials formed the evidence base to write a new guideline statement on the use of hormone therapy in patients Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited. receiving SRT…”
InfluentialSelf-citation
Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes
Preißer, F., Chun, F. K. ‐., Pompe, R. S., Heinze, A., Salomon, G., Graefen, M., Huland, H., & Derya Tilki, A. (2019) · European Urology · doi:10.1016/j.eururo.2019.01.048 · Cited by 128
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair
Shafi, A. A., McNair, C. M., McCann, J. J., Alshalalfa, M., Shostak, A., Severson, T., Zhu, Y., Bergman, A. M., Gordon, N., Mandigo, A. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20513-5 · Cited by 130
Self-citation
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
Gillessen, S., Bossi, A., Davis, I. D., Bono, J. S. D., Fizazi, K. S., James, N. D., Mottet, N., Shore, N. D., Small, E. J., Smith, M. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.11.002 · Cited by 124
“In RTOG 9601, OS was marginally superior when patients received 2 yr of bicalutamide (150 mg daily) plus sRT as compared with sRT alone [114].”
BackgroundMethodInfluentialSelf-citation
Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death
Derya Tilki, A., Chen, M., Wu, J., Huland, H., Graefen, M., Wiegel, T., Böhmer, D., Mohamad, O., Cowan, J. E., Feng, F. Y.-C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03714 · Cited by 113
Self-citation
Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
Calais, J., Czernin, J. G., Fendler, W. P., Elashoff, D. A., & Nickols, N. G. (2019) · BMC Cancer · doi:10.1186/s12885-018-5200-1 · Cited by 110
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer
Dess, R. T., Sun, Y., Jackson, W., Jairath, N. K., Kishan, A. U., Wallington, D. G., Mahal, B. A. V., Stish, B. J., Zumsteg, Z. S., Den, R. B., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0109 · Cited by 103
Self-citation
Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread
Barbosa, F. D. G., Queiroz, M. A., Nunes, R. F., Viana, P. C. C., Marin, J. F. G., Cerri, G. G., & Buchpiguel, C. A. (2019) · Radiographics · doi:10.1148/rg.2019180079 · Cited by 100
Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension
Hackman, G., Taari, K., Tammela, T. L. J., Matikainen, M. P., Kouri, M., Joensuu, T. K., Luukkaala, T. H., Salonen, A. J., Isotalo, T., Pétas, A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.07.001 · Cited by 99
Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis
Nead, K. T., Sinha, S., Yang, D. D., & Nguyen, P. L. (2017) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.07.016 · Cited by 96
Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
Jayadevappa, R., Chhatre, S., Malkowicz, S. B., Parikh, R. B., Guzzo, T. J., & Wein, A. J. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6562 · Cited by 98
Outcome After PSMA PET/CT–Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis
Schmidt-Hegemann, N.-S., Stief, C. G., Kim, T.-H., Eze, C., Kirste, S., Strouthos, I., Li, M., Schultze‐Seemann, W., Ilhan, H., Fendler, W. P., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.212563 · Cited by 96
“ADT was recommended to patients with evidence of PETpositive lesions for 2 y (2).”
Background
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate
Dess, R. T., Suresh, K., Zeléfsky, M. J., Freedland, S. J., Mahal, B. A. V., Cooperberg, M. R., Davis, B. J., Horwitz, E. M., Terris, M. K., Amling, C. L., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4922 · Cited by 89
Self-citation
Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate
Rozet, F., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mongiat-Artus, P., Ploussard, G., Mathiéu, R., Brureau, L., et al. (2018) · The French Journal of Urology · doi:10.1016/j.purol.2019.01.007 · Cited by 89
PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial
Bruycker, A. D., Spiessens, A., Dirix, P. R., Koutsouvelis, N., Semac, I., Liefhooghe, N., Iturriaga, A. G., Everaerts, W., Otte, F., Papachristofilou, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06911-4 · Cited by 83
“As two recent trials have suggested a progression-free and even overall survival benefit by adding temporary ADT to local therapy in case of biochemical recurrence [18, 19], a positive effect could also be expected for re-”
BackgroundMethod
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial
Parker, C. C., Kynaston, H., Cook, A. D., Clarke, N. W., Catton, C., Cross, W. R., Petersen, P. M., Persad, R. A., Pugh, C., Fred Saad, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00549-x · Cited by 83
Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers
Choi, E., Buie, J. D., Camacho, J., Sharma, P., & de Riese, W. T. W. (2022) · Research and Reports in Urology · doi:10.2147/rru.s303215 · Cited by 92
“This study showed in the ADT plus radiation arm significant higher rates in overall survival, but also decreased incidence of metastasis and cancer-related deaths compared to radiation therapy alone.(73) The clinical trial done by Warde et al confirmed the unequivocal benefits of combining ADT and Radiation therapy in…”
Result
Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features
Hwang, W. L., Tendulkar, R. D., Niemierko, A., Agrawal, S., Stephans, K. L., Spratt, D. E., Hearn, J. W. D., Koontz, B. F., Lee, W. R., Michalski, J. M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5230 · Cited by 80
Self-citation
Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality
Derya Tilki, A., Chen, M., Wu, J., Huland, H., Graefen, M., Braccioforte, M. H., Moran, B. J., & D'Amico, A. V. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4836 · Cited by 78
Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy
Fossati, N., Karnes, R. J., Colicchia, M., Boorjian, S. A., Bossi, A., Seisen, T., Muzio, N. G. D., Cozzarini, C., Chiorda, B. N., Fiorino, C., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.07.026 · Cited by 76
“Nowadays there is emerging evidence from randomised controlled studies that combination of hormones and SRT improves at least progression-free survival [30,31].”
Background
Role of the DNA damage response in prostate cancer formation, progression and treatment
Zhang, W., van Gent, D. C., Incrocci, L., van Weerden, W. M., & Nonnekens, J. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0153-2 · Cited by 79
A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer
Spratt, D. E., Dess, R. T., Zumsteg, Z. S., Lin, D. W., Tran, P. T., Morgan, T. M., Antonarakis, E. S., Nguyen, P. L., Ryan, C. J., Sandler, H. M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.027 · Cited by 75
Self-citation
Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : cancer de la prostate
Rozet, F., Mongiat-Artus, P., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mathiéu, R., Ploussard, G., Renard‐Penna, R., et al. (2020) · The French Journal of Urology · doi:10.1016/s1166-7087(20)30752-1 · Cited by 79
Best Approaches and Updates for Prostate Cancer Biochemical Recurrence
Simon, N. I., Parker, C. C., Hope, T. A., & Paller, C. J. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351033 · Cited by 70
Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)
Jereczek‐Fossa, B. A., Rojas, D. P., Zerini, D., Fodor, C. I., Viola, A., Fanetti, G., Volpe, S., Luraschi, R., Bazani, A., Rondi, E., et al. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180494 · Cited by 71
Cancer plasticity in therapy resistance: Mechanisms and novel strategies
Niu, X., Liu, W., Yinling, Z., Liu, J., Zhang, J., Li, B., Qiu, Y., Zhao, P., Wang, Z., & Wang, Z. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101114 · Cited by 68
Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy
Sawicki, L. M., Kirchner, J., Buddensieck, C., Antke, C., Ullrich, T., Schimmöller, L., Boos, J., Schleich, C., Schaarschmidt, B. M., Buchbender, C., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04308-5 · Cited by 67
Radiation Therapy for Prostate Cancer
Kamran, S. C., & D'Amico, A. V. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.08.017 · Cited by 67
French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease
Ploussard, G., Fiard, G., Barret, É., Brureau, L., Créhange, G., Dariane, C., Fromont, G., Gauthé, M., Mathiéu, R., Renard‐Penna, R., et al. (2022) · The French Journal of Urology · doi:10.1016/j.purol.2022.07.148 · Cited by 74
Green nanotechnology of MGF-AuNPs for immunomodulatory intervention in prostate cancer therapy
Khoobchandani, M., Khan, A. A., Katti, K. K., Thipe, V. C., Al-Yasiri, A. Y., Mohandoss, D. K. D., Nicholl, M. B., Lugão, A. B., Hans, C. P., & Katti, K. V. (2021) · Scientific Reports · doi:10.1038/s41598-021-96224-8 · Cited by 67
Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death
Derya Tilki, A., Chen, M., Wu, J., Huland, H., Graefen, M., Mohamad, O., Cowan, J. E., Feng, F. Y.-C., Carroll, P. R., & D'Amico, A. V. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02489 · Cited by 65
“This is particularly important given that the use of ADT and its duration in the post-RP setting has been shown in two prospective randomized trials(18,19) to be associated with the reduction of metastasis-free survival and in addition prolongation in overall survival in one study.(20) Third, during the conduct of the…”
BackgroundSelf-citation
Effects of exercise therapy in cancer patients undergoing radiotherapy treatment: a narrative review
Piraux, E., Caty, G. D., Nana, F. A., & Reychler, G. (2020) · SAGE Open Medicine · doi:10.1177/2050312120922657 · Cited by 69
SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
Stranne, J., Brasso, K., Brennhovd, B., Johansson, E., Jäderling, F., Kouri, M., Lilleby, W. A., Petersen, R. H., Mirtti, T. K., Pettersson, A., et al. (2018) · Scandinavian Journal of Urology · doi:10.1080/21681805.2018.1520295 · Cited by 62
“In light of the prospectively raised data on overall survival, post-operative RT includes 18–24 months of treatment with Bicalutamide 150mg daily [12].”
Background
Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group
Lieng, H., Hayden, A. J., Christie, D., Davis, B. J., Eade, T., Emmett, L., Holt, T., Hruby, G., Pryor, D. I., Shakespeare, T. P., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.06.027 · Cited by 62
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
Shore, N. D., Antonarakis, E. S., Cookson, M. S., Crawford, E. D., Morgans, A. K., Albala, D. M., Hafron, J. M., Harris, R. G., Saltzstein, D. R., Brown, G. A., et al. (2020) · The Prostate · doi:10.1002/pros.23967 · Cited by 62
“53).(48) Additionally, the 5‐year GETUG‐ AFU 16 trial has reported a benefit with 6 months ADT with RT vs no ADT, and the 10‐year MFS data will be reported soon.”
Angiogenesis Inhibition in Prostate Cancer: An Update
Sarkar, C., Goswami, S., Basu, S., & Chakroborty, D. (2020) · Cancers · doi:10.3390/cancers12092382 · Cited by 59
Salvage therapy for prostate cancer after radical prostatectomy
Zaorsky, N. G., Calais, J., Fanti, S., Derya Tilki, A., Dorff, T. B., Spratt, D. E., & Kishan, A. U. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00497-7 · Cited by 59
Impact of 68 Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis
Schmidt-Hegemann, N.-S., Eze, C., Li, M., Rogowski, P., Schaefer, C., Stief, C. G., Büchner, A., Zamboglou, C., Fendler, W. P., Ganswindt, U., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220855 · Cited by 58
“Likewise, radiotherapy plays a pivotal role in achieving tumor control in patients with persistent or recurrent prostatespecific antigen (PSA) after radical prostatectomy (3).”
Background
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation
Xie, W., Regan, M. M., Buyse, M. E., Halabi, S., Kantoff, P. W., Sartor, O. A., Soule, H. R., Berry, D. A., Clarke, N. W., Collette, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03114 · Cited by 58
“However, for an ICE to serve as a good surrogate for OS, there must be no confounding from salvage therapy for relapsed disease that can either cure the disease and/or prolong postrelapse survival to the point that competing risks of death affect the analysis.(22-27) Salvage prostate bed radiation after a prostatectom…”
BackgroundSelf-citation
Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions
McKay, R. R., Feng, F. Y.-C., Wang, A. Y., Wallis, C. J. D., & Moses, K. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279459 · Cited by 60
Self-citation
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer
Yang, D. D., Mahal, B. A. V., Muralidhar, V., Nezolosky, M. D., Vastola, M. E., Labe, S. A., Boldbaatar, N., King, M. T., Martin, N. E., Orio, P. F., et al. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.05.011 · Cited by 57
Self-citation
Patterns of failure after radical prostatectomy in prostate cancer – implications for radiation therapy planning after 68Ga-PSMA-PET imaging
Schiller, K., Sauter, K., Dewes, S., Eiber, M. J., Maurer, T., Gschwend, J. E., Combs, S. E., & Habl, G. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3746-9 · Cited by 57
Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial
Qi, X., Li, H., Gao, X., Qin, S., Zhang, M., Li, X., Li, X.-Y., Ma, M., Bai, Y., Li, X., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.09.047 · Cited by 57
DNA Damage Response in Prostate CancerPreprint
Schiewer, M. J., & Knudsen, K. E. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030486 · Cited by 58
“…advanced PCa, the standard of care is radiation therapy in conjunction with ADT based on significant survival benefits seen in large phase 3 clinical trials (Bolla et al. 1997, 2013; Widmark et al. 2009; Warde et al. 2011), including most recently the phase 3 RTOG 9601 (Shipley et al. 2017).”
Background
Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy
Robin, S., Jolicoeur, M., Palumbo, S., Zilli, T., Créhange, G., Hertogh, O. D., Derashodian, T., Sargos, P., Salembier, C., Supiot, S., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.11.010 · Cited by 56
Dual-resonance optical fiber lossy mode resonance immunoprobe for serum PSA detection
Dai, X., Wang, S., Wang, Y., Wang, X., Wu, X., Liu, X., Jiang, J., Xu, T., & Liu, T. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.117049 · Cited by 56
“The concentration of PSA is 0~4 ng/mL in the serum of healthy individuals, while a concentration of serum PSA greater than 4 ng/mL indicates a risk of PCa (McKiernan et al., 2016; Shipley et al., 2017).”
Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction
Müller, J., Ferraro, D. A., Muehlematter, U. J., Schüler, H. I. G., Kedzia, S., Eberli, D., Gückenberger, M., Kroeze, S. G. C., Sulser, T., SCHMID, D. M., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4203-0 · Cited by 56
Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature
Ploussard, G., Fossati, N., Wiegel, T., D'Amico, A. V., Hofman, M. S., Gillessen, S., Mottet, N., Joniau, S., & Spratt, D. E. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.01.001 · Cited by 55
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer
Kanesvaran, R., Castro, E., Wong, A. S. C., Fizazi, K. S., Chua, M. L. K., Zhu, Y., Malhotra, H., Miura, Y., Lee, J. L., Chong, F. L. T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100518 · Cited by 47
“001).(86) The randomised phase III GETUG-AFU 16 trial showed ADT to improve metastasis-free survival (HR 0.”
Background
Localized and Locally Advanced Prostate Cancer: Treatment Options
Achard, V., Panje, C. M., Engeler, D. S., Zilli, T., & Putora, P. M. (2021) · Oncology · doi:10.1159/000513258 · Cited by 46
PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
Markowski, M. C., Chen, Y., Feng, Z., Cullen, J. C., Trock, B. J., Suzman, D. L., Antonarakis, E. S., Paller, C. J., Rosner, I. L., Han, M., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.08.002 · Cited by 45
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)
Armstrong, W. R., Kishan, A. U., Booker, K. M., Grogan, T., Elashoff, D. A., Lam, E. C., Clark, K. J., Steinberg, M. L., Fendler, W. P., Hope, T. A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.01.012 · Cited by 44
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
Tran, P. T., Lowe, K. J., Tsai, H., Song, D. Y., Hung, A., Hearn, J. W. D., Miller, S. R., Proudfoot, J. A., Deek, M. P., Phillips, R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01662 · Cited by 43
“Participants were also counseled about the positive survival results of the NRG/RTOG 96-01 clinical trial and elected to forgo treatment with high-dose bicalutimide.(15)”
MethodSelf-citation
Androgen‐deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?
McHugh, D. J., Root, J. C., Nelson, C. J., & Morris, M. J. (2018) · Cancer · doi:10.1002/cncr.31153 · Cited by 43
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy
Morgan, T. M., Boorjian, S. A., Buyyounouski, M. K., Chapin, B. F., Chen, D. Y. T., Cheng, H. H., Chou, R., Jacene, H. A., Kamran, S. C., Kim, S. K., et al. (2024) · The Journal of Urology · doi:10.1097/ju.0000000000003891 · Cited by 42
Prostate-specific Membrane Antigen Positron Emission Tomography–detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation
Kroeze, S. G. C., Henkenberens, C., Schmidt-Hegemann, N.-S., Vogel, M. M. E., Kirste, S., Becker, J., Burger, I. A., Derlin, T., Bartenstein, P., Eiber, M. J., et al. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.08.012 · Cited by 42
Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer
Bukavina, L., Luckenbaugh, A. N., Hofman, M. S., Hope, T., Kamran, S. C., Murphy, D. G., Yamoah, K., & Ost, P. (2022) · European Urology · doi:10.1016/j.eururo.2022.10.024 · Cited by 43
RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate
Rozet, F., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mongiat-Artus, P., Ploussard, G., Mathiéu, R., Brureau, L., et al. (2018) · The French Journal of Urology · doi:10.1016/j.purol.2018.08.011 · Cited by 42
Retracted
The contemporary management of prostate cancer
Chakrabarti, D., Albertsen, P. C., Adkins, A., Kishan, A. U., Murthy, V., Parker, C. C., Pathmanathan, A. U., Reid, A. H. M., Sartor, O., van As, N. J., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70020 · Cited by 50
Self-citation
Delineating sites of failure following post-prostatectomy radiation treatment using 68 Ga-PSMA-PET
Byrne, K., Eade, T., Kneebone, A. B., Guo, L., Hsiao, E., Schembri, G. P., Kwong, C., Hunter, J., Emmett, L., & Hruby, G. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.10.022 · Cited by 40
Assessment of biochemical recurrence of prostate cancer (Review)
Lin, X., Kapoor, A., Gu, Y. J., Chow, M. J., Xu, H., Major, P. P., & Tang, D. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4893 · Cited by 44
“It appears that SRT plus hormone therapy (bicalutamide) improved the outcome (258,259).”
Self-citation
Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer
Gordon, L. G., Elliott, T. M., Joshi, A., Williams, E. D., & Vela, I. (2020) · Clinical & Experimental Metastasis · doi:10.1007/s10585-020-10027-1 · Cited by 41
Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series
Gandaglia, G., Fossati, N., Karnes, R. J., Boorjian, S. A., Colicchia, M., Bossi, A., Seisen, T., Cozzarini, C., Muzio, N. G. D., Chiorda, B. N., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.11.020 · Cited by 39
Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival
Jackson, W., Suresh, K., Tumati, V., Allen, S. G., Dess, R. T., Salami, S. S., George, A. K., Kaffenberger, S. D., Miller, D. C., Hearn, J. W. D., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.12.023 · Cited by 39
Self-citation
Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time
Spratt, D. E., McHugh, D. J., Morris, M. J., & Morgans, A. K. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200319 · Cited by 39
Adjuvant and Salvage Radiation Therapy After Prostatectomy: ASTRO/AUA Guideline Amendment, Executive Summary 2018
Pisansky, T. M., Thompson, I. M., Valicenti, R. K., D'Amico, A. V., & Selvarajah, S. (2019) · Practical Radiation Oncology · doi:10.1016/j.prro.2019.04.008 · Cited by 39
Self-citation
A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
Abghari-Gerst, M., Armstrong, W. R., Nguyen, K., Calais, J., Czernin, J. G., Lin, D. W., Jariwala, N., Rodnick, M. E., Hope, T. A., Hearn, J. W. D., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262412 · Cited by 41
“BCR after definitive therapy is common, especially in higher-risk disease, and may affect more than 50% of patients over the long term (2,3).”
Background
Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group
Lieng, H., Kneebone, A. B., Hayden, A. J., Christie, D., Davis, B. J., Eade, T., Emmett, L., Holt, T., Hruby, G., Pryor, D. I., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.05.016 · Cited by 37
Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer
Linxweiler, J., Hammer, M., Muhs, S., Kohn, M., Pryalukhin, A. E., Veith, C., Bohle, R. M., Stöckle, M., Junker, K., & Saar, M. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2803-5 · Cited by 36
The complementary value of intraoperative fluorescence imaging and Raman spectroscopy for cancer surgery: combining the incompatibles
Lauwerends, L. J., Abbasi, H., Schut, T. C. B., van Driel, P. B. A. A., Hardillo, J. A., Santos, I. P., Barroso, E. M., Koljenović, S., Vahrmeijer, A. L., de Jong, R. J. B., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05705-z · Cited by 36
Metabolic response to radiation therapy in cancer
Read, G. H., Bailleul, J., Vlashi, E., & Kesarwala, A. H. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23379 · Cited by 41
Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047)
Parker, C. C., Clarke, N. W., Cook, A. D., Petersen, P. M., Catton, C., Cross, W. R., Kynaston, H., Persad, R. A., Fred Saad, C., Logue, J. P., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.07.026 · Cited by 34
“The RTOG 9601 trial, which tested androgen blockade using bicalutamide monotherapy rather than testosterone suppression using GnRH therapy, reported an improvement in overall survival (HR = 0.77) as well as MFS [10].”
Influential
Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities
Martínez‐Bosch, N., Rodríguez‐Vida, A., Juanpere-Rodero, N., Lloreta, J., Rovira, A., Albanell, J., Joaquim Bellmunt, B., & Navarro, P. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0183-5 · Cited by 34
Management Options for Biochemically Recurrent Prostate Cancer
Fakhrejahani, F., Madan, R. A., & Dahut, W. L. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0462-4 · Cited by 33
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy
Zamboglou, C., Strouthos, I., Sahlmann, J., Farolfi, A., Serani, F., Medici, F., Cavallini, L., MORGANTI, A. G., Trapp, C., Koerber, S. A., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.04.048 · Cited by 33
Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer
Ramey, S. J., Agrawal, S., Abramowitz, M. C., Moghanaki, D. M., Pisansky, T. M., Efstathiou, J. A., Michalski, J. M., Spratt, D. E., Hearn, J. W. D., Koontz, B. F., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.10.009 · Cited by 33
“publications of RTOG 96-01 [10] and GETUG-AFU 16 [11], the benefit of ADT with postprostatectomy RT is becoming more established; however, neither evaluated WPRT.”
BackgroundMethodSelf-citation
Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research
Behring, M. P., Hale, K., Ozaydin, B., Grizzle, W. E., Sodeke, S. O., & Manne, U. (2019) · Cancer · doi:10.1002/cncr.32495 · Cited by 32
Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series
Francolini, G., Jereczek‐Fossa, B. A., Cataldo, V. D., Simontacchi, G., Marvaso, G., Zerella, M. A., Gentile, P., Bianciardi, F., Allegretta, S. A., Detti, B., et al. (2019) · British Journal of Urology · doi:10.1111/bju.14924 · Cited by 32

Authors: Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., Sartor, O., Patel, M. P., Bahary, J.-P., Zietman, A. L., Pisansky, T. M., Zeitzer, K. L., Lawton, C. A. F., Feng, F. Y., Lovett, R. D., Balogh, A. G., Souhami, L., Rosenthal, S. A., Kerlin, K. J., Dignam, J. J., Pugh, S. L., & Sandler, H. M.
Affiliations: Cedars-Sinai Medical Center (US)
Tulane University (US)
ORCID: Shipley, William U.
Major, Pierre P.
Grignon, David J.
Sartor, Oliver
Bahary, Jean-Paul
Zietman, Anthony L.
Pisansky, Thomas M.
Zeitzer, Kenneth L.
Feng, Felix Y.
Rosenthal, Seth A.
Dignam, James J.
Pugh, Stephanie L.
Sandler, Howard M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-02-02
Volume: 376
Issue: 5
Pages: 417-428
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1607529
PMC: PMC5444881
OpenAlex: W2585109238
Cited by: 663
References: 29
Citations by year: 2026: 32 · 2025: 54 · 2024: 65 · 2023: 50 · 2022: 63 · 2021: 84 · 2020: 81 · 2019: 86 · 2018: 78 · 2017: 68
FWCI: 70.79
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (UG1CA189867, U10CA180868, U10CA180801, U10CA021661, U10CA180822)
Topics: Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: recurrent prostate cancer, salvage radiotherapy, antiandrogen therapy, bicalutamide, prostate-specific antigen, radical prostatectomy, overall survival, metastatic prostate cancer, gynecomastia, androgen deprivation therapy, lymph node dissection, long-term follow-up
MeSH terms: Aged, Aged, 80 and over, Androgen Antagonists, Anilides, Combined Modality Therapy, Double-Blind Method, Follow-Up Studies, Gynecomastia, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Nitriles, Prostatectomy, Prostatic Neoplasms, Radiotherapy, Tosyl Compounds, Incidence, Survival Rate, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks